The following is a collection of featured thoracic articles in press from the Journal of Thoracic and Cardiovascular Surgery (JTCVS). To read the latest issue, browse the feature video library and other journal highlights please visit www.jtcvs.org
Please add admin@aats.org to your Safe Senders list
LUNG CANCER
Postoperative Day One Discharge Following Anatomic Lung Resection: An STS Database Analysis
Philip A. Linden, MD, Yaron Perry, MD, Stephanie Worrell, MD, Amelia Wallace, MS, Luis Argote-Greene, MD, Vanessa P. Ho, MD, MPH, Christopher W. Towe, MD
Postoperative day 1 discharge after lobectomy can be achieved without an increased risk of readmission or death. It can be considered for select patients.
Read Now
Commentary: Winning the Race after Lung Surgery: The Tortoise or the Hare?
Abbas E. Abbas, MD, MS, FACS
Next-day discharge after lung surgery requires careful planning to avoid complications and readmissions. Anatomic lung resection should not be considered a minor procedure.
Outcomes of major complications after robotic anatomical pulmonary resection
Christopher Cao, MBBS, PhD, Brian E. Louie, MD, Franca Melfi, MD, Giulia Veronesi, MD, Rene Razzak, MD, Gaetano Romano, MD, Pierluigi Novellis, MD, Neel K. Ranganath, MD, Bernard J. Park, MD
The incidence of major complications after robotic resections was low and associated with a number of identified factors.
Commentary: Robotic Anatomic Pulmonary Resection: Cinderella has left the house
Richard S. Lazzaro, MD, FACS
Robotic anatomical resection is safe and effective. The time is now to develop mentoring workshops and standardized training programs for robotic-assisted VATS; Cinderella has left the house.
Commentary: Robotic Anatomic Lung Resection: Raising The Bar Of Our Expectations In Treating Lung Cancer
By demonstrating a low complication rate after anatomic lung resection, robotic surgery establishes the safety of the surgical management of lung cancer, comparing favorably with nonsurgical modalities.
THYMUS CANCER
Long-Term Disease-Specific Outcomes of Thymic Malignancies Presenting with de novo Pleural Metastasis
Giye Choe, MD, Amanda Ghanie, BS, Gregory Riely, MD, Andreas Rimner, MD, Bernard J. Park, MD, Manjit S. Bains, MD, Valerie W. Rusch, MD, Prasad S. Adusumilli, MD, Robert J. Downey, MD, David R. Jones, MD, James Huang, MD
Surgical resection of stage IVa thymic malignancies can be performed with prolonged survival and, in well-selected patients, durable surgical remission.
Commentary: Expanding the Legacy of Unusual Malignancy Research
Todd L. Demmy, MD
The study of unusual tumors may be ideal to reengineer cancer database systems because of the lack of practical research alternatives and the modest resources (low volume) needed to test new designs.
Commentary: Pleural Metastases in Thymic Tumors: Is Surgery the Answer?
C. Corbin Frye, MD, Shea Harrison, MD, Varun Puri, MD, MSCI
Thymoma and thymic cancer with pleural metastases can be treated with aggressive surgical therapy.
Commentary: Effect of debulking?
Hiroshi Date, MD
Surgical resection of stage IVa thymic malignancies may result in encouraging long-term survival in well-selected patients.
LUNG TRANSPLANT
Outcomes of marginal donors for lung transplantation after ex vivo lung perfusion: A systematic review and meta-analysis
Dong Tian, MD, Yu Wang, MD, Haruhiko Shiiya, MD, Chang-Bo Sun, MD, Yukari Uemura, MD, PhD, Masaaki Sato, MD, PhD, Jun Nakajima, MD, PhD
The outcomes after lung transplantation of ex vivo lung perfusion on marginal donor lungs are comparable with those of standard lung transplantation without ex vivo lung perfusion treatment.
Commentary: Levelling up the evidence!
Konrad Hoetzenecker, MD, PhD
There is an increasing body of evidence pointing toward the routine use of ex vivo lung perfusion for marginal donor lungs.
Commentary: A positive out of body experience for lungs
Norihisa Shigemura, MD, PhD, Michael K. Hsin, MD
EVLP increases utilization of marginal donor lungs without compromising early lung transplant outcomes, but further refinements may help to achieve even better long-term benefits.
PERIOPERATIVE MANAGEMENT
Pre-emptive pain management program is associated with reduction of opioid prescriptions after benign minimally invasive foregut surgery
Min P. Kim, MD, FACS, Carla Godoya, Duc T. Nguyen, MD, PhD, Leonora M. Meisenbach, DNP, RN, ACNP-BC, Ray Chihara, MD, PhD, Edward Y. Chan, MD, FACS, Edward A. Graviss, PhD, MPH, FIDSA
A preemptive pain-management program is associated with opioid-free discharge after foregut surgery.
Commentary: Role of pre-emptive analgesia in reversing the opioid epidemic
Mohamed K. Kamel, MD
The use of pre-emptive analgesia following minimally invasive foregut surgery can significantly decrease opioid prescriptions at discharge, yet with no compromise in the adequacy of pain control.
Can Preemptive Analgesia Decrease Opioids Use After Foregut Laparoscopic Surgery?
Ivan Azevedo, MD, Paula Ugalde Figueroa, MD
A preemptive pain management program in patients who undergo foregut surgery might decrease the amount of opioids prescribed postoperatively.
FEATURED VIDEO
Video Legend: Bupivacaine injections reduce opioids
View Now